Loading market dashboard
DaVita Inc.
DVAHealthcareNYSEUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
DVA expands kidney-care reach with integrated CKD/ESKD coordination and 2026 AI scheduling tech to boost dialysis efficiency.
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock?
HRB, DVA and VLO made it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 4th, 2026.
DVA raises guidance on stronger dialysis volumes and reimbursement gains, but rising patient-care and technology costs could squeeze margins.
HRB, DVA and LCUT made it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 2nd, 2026.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
CNC, SANM and DVA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on May 26, 2026.
LCUT, GECC, ARKO, PBI and DVA have been added to the Zacks Rank #1 (Strong Buy) List on May 26, 2026.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
These four GARP stocks combine discounted PEG ratios with strong growth potential, offering investors a balanced strategy for 2026.
Investors target stocks that have been on a bullish run. Stocks like MUSA, DVA, MCHP and CVE are seeing price strength, and the momentum is likely to continue.
GPRE, DVA and SNX made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 21, 2026.
DVA, TAL, and LCUT it to the Zacks Rank #1 (Strong Buy) growth stocks list on May 21, 2026.
UVE, LCUT and DVA made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 19, 2026.
DVA, PBI, and LCUT it to the Zacks Rank #1 (Strong Buy) growth stocks list on May 19, 2026.
DaVita Sets Bold 2030 Community Care Commitments After Exceeding Prior Five-Year ESG Goals PR Newswire DENVER, M
Kidney care leader launches its next chapter of measurable impact for patients, teammates, and communities. DENVER, May 18, 2026 /PRNewswire/ -- DaVita today announced its 2030 Community Care commitments, a new set of long-term goals, focused on improving patient outcomes, supporting the expansion of economic opportunity for teammates, and strengthening community and environmental resilience.
Low-PEG stocks like DaVita, AR, PBF and Popular stand out as value plays with strong growth potential and discounted valuations.
NXST, LCUT and DVA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on May 14th, 2026.
DaVita Inc. (DVA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
AR, DVA and WOOF made it to the Zacks Rank #1 (Strong Buy) growth stocks list on May 12th, 2026.
These highly ranked medical stocks have been capitalizing on their sales expansion, and their defensive or secular growth profiles could become even more attractive if an economic downturn emerges.
Does DaVita HealthCare (DVA) have what it takes to be a top stock pick for momentum investors? Let's find out.
DaVita HealthCare (DVA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today May 8th:
ATLC, DVA and AMN made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 8, 2026.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DaVita Inc. is upgraded to a Buy following robust Q1 results and a 23% post-earnings stock surge. DVA's Q1 non-GAAP EPS of $2.87 beat consensus, with revenue up 6% year-over-year and management raising guidance. Mid-teens EPS growth is expected through 2026, with a 10%+ FCF yield and a modest P/E ratio supporting valuation.
DENVER, May 6, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) today announced that its chief financial officer, Joel Ackerman, and its group vice president of investor relations, Nic Eliason, will participate in a fireside chat with investors at the BofA Securities 2026 Health Care Conference on Tuesday, May 12th, 2026 at 5:20 pm Eastern Daylight Time. To view the live webcast, visit the BofA page and create a free registration.
DVA's first-quarter 2026 results benefit from expanding margins and steady dialysis demand across its broad clinic network.
DaVita Inc. (DVA) Q1 2026 Earnings Call Transcript
DaVita HealthCare (DVA) came out with quarterly earnings of $2.87 per share, beating the Zacks Consensus Estimate of $2.41 per share. This compares to earnings of $2 per share a year ago.
DaVita on Tuesday raised its forecast for annual adjusted profit after beating Wall Street estimates for first-quarter results, betting on steady demand for its kidney dialysis services.
DENVER, May 5, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended March 31, 2026. "DaVita's foundation is clinical excellence, driven by operating rigor that produces durable results," said Javier Rodriguez, CEO of DaVita Inc. "We have consistently delivered exceptional clinical outcomes and strong financial performance, and this quarter is no exception.
DaVita HealthCare (DVA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
In the latest trading session, DaVita HealthCare (DVA) closed at $151.99, marking a +1.28% move from the previous day.
Directors bring compelling mix of aerospace and defense expertise, leadership experience, and financial and capital markets backgrounds Honeywell spin-off of Honeywell Aerospace expected to be completed on June 29, 2026 Management will provide details on Honeywell Aerospace's value creation and financial outlook at an Investor Day on June 3, 2026 CHARLOTTE, N.C., April 28, 2026 /PRNewswire/ -- Honeywell (NASDAQ: HON) today announced the anticipated Board of Directors for Honeywell Aerospace, which will be one of the largest publicly listed pure-play aerospace and defense companies following its planned spin-off from Honeywell.
In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $152.42, denoting a +1.68% move from the preceding trading day.
DENVER, April 20, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss first quarter results on Tuesday, May 5, 2026, at 5:00 p.m. Eastern Time.
Mitsubishi stock has skyrocketed in part due to rising demand for LNG, copper, and other materials. Another Japanese stock, Marubeni, has also been a big winner for Buffett this year.
DaVita HealthCare (DVA) closed the most recent trading day at $144.57, moving 3.27% from the previous trading session.
City Holding Co. decreased its position in shares of DaVita Inc. (NYSE: DVA) by 83.4% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 720 shares of the company's stock after selling 3,630 shares during the quarter. City Holding Co.'s holdings in
DaVita HealthCare (DVA) closed the most recent trading day at $150.68, moving +1.51% from the previous trading session.
DVA rides on EPS growth and early IKC profitability, but flat treatment volumes and reimbursement risks raise questions about sustaining momentum.
DaVita HealthCare (DVA) closed at $145.58 in the latest trading session, marking a -3.17% move from the prior day.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
In the most recent trading session, DaVita HealthCare (DVA) closed at $152.37, indicating a -1.33% shift from the previous trading day.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Disclaimer: The statements contained in this document are solely those of the authors and do not necessarily reflect the views or policies of CMS. The authors assume responsibility for the accuracy and completeness of the information contained in this document.
In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $149.98, denoting a +1.19% move from the preceding trading day.
An aging population and rising AI adoption boost demand in the Zacks Medical - Outpatient and Home Healthcare industry. DGX, DVA, OPCH and ADUS stand to benefit.
Series A co-led by Abingworth, DaVita Venture Group, and F-Prime with participation from Curie.Bio, SymBiosis, and U.S. Renal Care Partnership with Alebund Pharmaceuticals to gain exclusive global development and commercial rights outside of Greater China for AP306, a differentiated pan phosphate transporter inhibitor, the only agent blocking the active transport of phosphate Advancing Phase 2b clinical development of AP306 as a monotherapy for hyperphosphatemia in patients with chronic kidney disease on dialysis REDWOOD CITY, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- R1 Therapeutics, Inc (“R1”), a clinical-stage biopharmaceutical company focused on the development of first-in-class therapies for patients with kidney disease, today announced its launch with an oversubscribed $77.5 million Series A financing, along with the exclusive global license to develop and commercialize AP306 outside of Greater China from China-based Alebund Pharmaceuticals, Ltd.
Investors target stocks that have been on a bullish run. Stocks like STRA, SHIP, DVA and FE are seeing price strength, and the momentum is likely to continue.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Aquatic Capital Management LLC boosted its holdings in shares of DaVita Inc. (NYSE: DVA) by 370.5% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 51,218 shares of the company's stock after purchasing an additional 40,333 shares during the
The recent oil price spikes increase the appeal of Chevron, Berkshire Hathaway's largest oil and gas holding. Rising market share could mean a higher valuation ahead for Domino's.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
